Pilot Study of RNS60 in Allergen-induced Bronchoconstriction

Inclusion Criteria: * Males or females with mild asthma (as defined by the National Institutes of Health 2002 Guidelines for the Diagnosis and Management of Asthma (2)) with symptoms more than 2 times a week but less than once per day with normal FEV1 (\> 80% predicted). * Clinical history of allergic symptoms to cat or dust mite allergen and demonstrated skin reactivity. * Subjects must have a lifetime total of less than 5 pack years with no smoking in the previous 5 years. * Willing and able to give informed consent and adhere to the study protocol requirements. * Expressed the desire to participate in the study in an interview with the principal investigator (PI). * Age between 18 and 50 years. Exclusion Criteria: * Women of childbearing potential who are documented to be pregnant (based on blood beta-human chorionic gonadotropin \[HCG\] testing) or who are nursing. * The presence of spontaneous asthmatic episode or clinical evidence of upper respiratory tract infection within the previous 6 weeks. * Participation in research study involving a drug or biologic during the 30 days prior to the study. * Intolerance to albuterol, atropine, or lidocaine. * Antihistamines within 7 days of the screening visit. * Known exposure to agents that are associated with pulmonary disease (i.e. asbestos, silica). * Presence of other known pulmonary disease, coronary disease, congestive heart failure, ventricular arrhythmias, history of a cerebrovascular accident, renal failure (or creatinine \> 1.5, if known), history of anaphylaxis, cirrhosis, diabetes mellitus or presence of a significant disease, which in the opinion of the PI would pose a significant risk for the subject or confound the results of the study. * Use of systemic steroids, increased use of inhaled steroids, use of beta blockers and monoamine oxidase (MAO) inhibitors or a visit for an asthma exacerbation within 1 month of the screening visit. * A history of asthma-related respiratory failure requiring intubation. * A history of hospitalization for asthma. * Subjects with a high possibility of poor compliance with the study as judged by the PI. * Unresponsive to bronchodilator agents. * Quantitative skin prick test at or below a dilution level of standardized cat allergen extract of 1:2048 (4.88 BAU/ml) for subjects being challenged with cat allergen. * Quantitative skin prick test at or below a dilution level of standardized mite allergen extract of 1:2048 (4.88 AU/ml) for subjects being challenged with either mite allergen. * Subjects who, by participating in any research study, will have a cumulative radiation dose exceeding 50 mSv in the previous year. * Contraindication to Methacholine challenge testing (heart attack or stroke in last 3 months, uncontrolled hypertension, or known aortic aneurysm). * Body Mass Index (BMI) \> 32. * Individuals with known allergy or hypersensitivity to FDG will be excluded.